When can patients expect introduction of Prostvac as a treatment option for localized Adenocarcinoma?
P Ca patients with localised lesions with low to intermediate risk are faced with the side effects of radical therapies. There is news of an ongoing trial of Prostvac as immunotherapy for localised P Ca to halt disease progression. Is it possible to share the current status please? Thanks.